Navidea Biopharmaceuticals (FRA:NO1A) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Navidea Biopharmaceuticals COGS-to-Revenue?

Navidea Biopharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was €0.00 Mil.

Navidea Biopharmaceuticals's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Navidea Biopharmaceuticals's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

Navidea Biopharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Navidea Biopharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals COGS-to-Revenue Chart

Navidea Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.30

0.25

0.01

12.43

Navidea Biopharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															17.00	47.00	-	-	-

Navidea Biopharmaceuticals COGS-to-Revenue Calculation

Navidea Biopharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.174	/	0.014
	=	12.43

Navidea Biopharmaceuticals's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Navidea Biopharmaceuticals (FRA:NO1A) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Navidea Biopharmaceuticals's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Navidea Biopharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Navidea Biopharmaceuticals (FRA:NO1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (FRA:NO1A) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NAVB:USA

Address

4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552

Website

https://www.navidea.com

Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

Navidea Biopharmaceuticals (FRA:NO1A) Headlines

No Headlines